ReviewMissouri medicine
Injections vs. Scalpels: Where Do Surgery and GLP-1's Align in Modern Obesity treatment?
Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advancements in pharmacologic treatment of obesity and metabolic disease with nutrient-stimulated hormones (NuSH), particularly Semaglutide and Tirzepatide, have been revolutionary, showing weight reduction results comparable to some surgical options. This is especially promising as, despite the proven efficacy and safety of metabolic/bariatric surgery (MBS), its utilization has remained quite limited. This review article discusses the current literature on the comparative effectiveness of these two treatments and their impact on comorbidities such as type 2 diabetes mellitus (DM2) and cardiovascular disease. While weight reduction with these NewSH's (sic) appears similar to a sleeve gastrectomy, though significantly less than gastric bypass, MBS remains the gold standard treatment for patients with more severe obesity especially those with higher cardiometabolic disease burden.
Indexed as
Identifiers
40787019PMC12331298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.